Helixmith
Seoul, KR
Hybrid — also manufactures internal programs
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (3)
○ EMA GMP
○ MHRA GMP
Quick Facts: Helixmith
- Signal Score
- 59.0/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- Seoul, KR
- Modalities
- Plasmid, AAV
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Helixmith
Hybrid developer + CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesPlasmid, AAV
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Profile-based capacity assessment
Recent Press3 articles
Recent News 3 articles
[Medical & Bio Briefs] Helixmith Submits Clinical Trial Protocol for Gene Therapy Engensis to US FDA, and More - 동아사이언스
[Medical & Bio Briefs] Helixmith Submits Clinical Trial Protocol for Gene Therapy Engensis to US FDA, and More 동아사이언스
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals Barchart
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals Barchart.com
Frequently Asked Questions About Helixmith
What is Helixmith's CDMO Signal Score?
Helixmith has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Helixmith for a manufacturing program?
Use the free AI matchmaker to compare Helixmith against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 81.0
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid
Ascend Advanced Therapies
London, United Kingdom
Signal Score: 78.1
AAV, Lentiviral, Plasmid